The finding by Singh and colleagues that varenicline is associated with an increased risk of serious adverse cardiovascular events1 is not surprising because varenicline is frequently associated with hypertension.2,3 An elevation in blood pressure, however small, increases the risk of adverse cardiovascular outcomes.4 Before approving varenicline, the US Food and Drug Administration (FDA) should have mandated that the manufacturer provide the FDA with data on cardiovascular safety.
References
- 1.Singh S, Loke YK, Spangler JG, et al. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359–66 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Physician’s desk reference. 64th ed Montvale (NJ): Thomson; 2010. p. 2715 [Google Scholar]
- 3.Drug facts and comparisons. St. Louis (MO): Facts and Comparisons; 2011. p. 1115 [Google Scholar]
- 4.Weber MA. The ALLHAT report: a case of information and misinformation. J Clin Hypertens (Greenwich) 2003;5:9–13 [DOI] [PMC free article] [PubMed] [Google Scholar]